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CaMK-II is a PKD2 target  
that stabilizes cilia
Rothschild et al., Development 2011; 138: 3387–3397; doi:10.1242/dev.066340
Polycystic kidney disease is a ciliopathy believed to be due to 
defects in Ca2+ signaling. Autosomal dominant polycystic kid-
ney disease is caused by mutations in the polycystins PKD1 and 
PKD2. While PKD1 is a large receptor-like integral membrane 
protein with an extracellular N-terminus with motifs for cell–cell 
and cell–matrix interactions, PKD2 is a member of the transient 
receptor potential (TRP) superfamily of nonselective Ca2+-per-
meable ion channels found in plasma membranes, endoplasmic 
reticulum, and primary cilium. The intracellular terminals of 
both PKD1 and PKD2 contain coiled-coil domains that enable 
formation of a receptor–channel complex where activation of 
PKD1 induces Ca2+ entry via PKD2 and thus regulates levels 
of intracellular Ca2+. A large amount of work in a variety of 
mammalian and zebrafish models has shown that diminished 
activation of both intracellular Ca2+ signals leads to kidney cyst 
formation. One potential mediator of normal Ca2+ action is 
CaMK-II, a conserved calmodulin-dependent protein kinase; 
prolonged Ca2+ stimulation converts CaMK-II into an acti-
vated state that, in the zebrafish, is detected in the forebrain, ear, 
and kidney. In a recent study, Rothschild et al. found activated 
CaMK-II during early zebrafish development in specific cili-
ated tissues, including cells of the nervous system, the inner ear, 
and the pronephric kidney. Suppression of CaMK-II (camk2g1) 
induced pronephric cysts and resulted in disassembly of cilia and 
a decrease in their number, and any remaining cilia were immo-
bile. Moreover, kidney-targeted dominant-negative CaMK-II also 
caused pronephric cystogenesis. Of great interest is the authors’ 
finding that expression of constitutively active CaMK-II rescued 
cyst development in animals with knock-down of pkd2 (Figure). 
Thus, in the developing kidney, CaMK-II activation was found to 
be dependent on PKD2 Ca2+ and was capable of restoring proper 
kidney development in PKD2-deficient embryos. These findings 
indicate that CaMK-II is a natural transducer of PKD2 Ca2+ that 
enables both normal development and cilia stability. This elegant 
study has implications for other ciliated tissues and identifies a 
potential new therapeutic target for autosomal dominant poly-
cystic kidney disease.
Juan Oliver
Acute kidney injury after  
liver transplantation in a rat  
model of syngeneic orthotopic  
liver transplantation
Wang et al., Lab Invest 2011; 91: 1158–1169; doi:10.1038/labinvest.2011.59
Orthotopic liver transplantation (OLT) is indicated for patients 
with end-stage liver disease of almost any etiology. Acute kid-
ney injury (AKI) is a frequent complication after OLT and unfa-
vorably affects prognosis after liver transplantation (LT). AKI 
occurs in 80% of cases in the first 48 hours after LT. Post-LT AKI 
increases length of stay, cost, and mortality and is an important 
risk factor for chronic kidney disease and end-stage renal dis-
ease. Although post-LT AKI is common, its mechanism remains 
unclear. Risk factors such as intraoperative hemodynamic insta-
bility, post-reperfusion graft function, infection, and nephrotoxic 
drugs may predispose to post-LT AKI. Wang and colleagues 
used the rat model of syngeneic orthotopic LT (SOLT) to inves-
tigate the mechanism of post-LT AKI. They hypothesized that 
the condition of the graft, rather than intraoperative hemody-
namic instability, has an important role in post-LT AKI in the 
SOLT model. Rats were randomly assigned into four groups: 
sham operated, vessel clamped, full-size LT, and reduced-size 
LT. The authors identified AKI in both the full-size and the 
reduced-size LT groups. In addition to renal tubular necrosis 
and apoptosis, renal peritubular capillary injury was also pre-
sent. Pathological changes were more severe in the reduced-size 
than in the full-size LT group. Interleukin (IL)-1b, IL-6, tumor 
necrosis factor-a (TNF-a), and monocyte chemotactic protein-1 
(MCP-1) upregulation was found in liver tissue 6 hours after LT. 
The serum concentration of IL-6 and TNF-a was also increased 
at 6 hours after LT. The activated inflammatory response in renal 
tissue consisted of increased macrophage infiltration and upregu-
lated IL-1b, IL-6, and TNF-a. The circulating proinflammatory 
cytokines act on distant organs such as the lung and kidney. The 
systemic inflammatory response induced by LT was the initiating 
factor in post-LT AKI.
This is the first study to investigate the pathological mechanism 
of AKI in an animal model of SOLT. The results demonstrate that 
protection of the liver graft and inhibition of the systemic inflam-
matory response are vital in reducing the risk of post-LT AKI. This 
interesting study has several limitations, as some important risk 
factors of AKI in human LT are not included in the study. When 
syngeneic rats are used, immunosuppressive antirejection therapy 
Constitutively active (T287D) CaMK-II reverses pronephric 
developmental defects. (a–f) Lateral views of entire embryos (a–c) and 
the cloaca (d–f; arrows indicate the end of the cloaca) after injection of 
pkd2 morpholino with or without constitutively active CaMK-II (c). (g–i) 
Immunostaining a1 Na+/K+-ATPase identifies the pronephric ducts. hpf, 
hours post-fertilization.
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is not required. The operation was carried out on healthy animals, 
chronic liver disease was not present in the recipients, and the 
long-term effects of LT on the kidneys need to be clarified.
Marc De Broe
Vasopressin-independent  
targeting of aquaporin-2
Olesen et al., Proc Natl Acad Sci USA 2011; 108: 12949–12954; doi:10.1073/
pnas.1104691108
Vasopressin controls water balance by regulating water per-
meability in the kidney collecting duct; by binding to its GS 
protein-coupled type 2 receptor (V2R) in principal cells, it trig-
gers accumulation of aquaporin-2 (AQP2) in the apical plasma 
membrane, thereby allowing water to be reabsorbed and the 
urine to concentrate. Vasopressin intracellular signaling in the 
collecting duct includes increased cyclic adenosine monophos-
phate (cAMP) and protein kinase-dependent phosphorylation of 
AQP2. Although there is little doubt that urinary concentration is 
critically dependent on vasopressin, there is some evidence that 
alternative mechanisms may also regulate water permeability. 
For example, dehydration was found to reverse the diuresis and 
AQP2 downregulation induced by an antagonist to the V2R. In a 
recent communication, Olesen et al. examined the hypothesis that 
E-prostanoid signaling might be involved in AQP2 regulation. 
Prostaglandin E2 (PGE2) has multiple actions, probably due to its 
ability to stimulate four different receptors (EP1–EP4) and poten-
tially initiate different intracellular signaling cascades. PGE2 is 
synthesized and released in the collecting duct, which expresses all 
four EP receptors, and both EP2 and EP4 can signal via increased 
cAMP. Interestingly, at sites where EP1–EP4 are present, includ-
ing the collecting duct, PGE2 is known to have opposing effects; 
for example, PGE2 has been shown both to increase water per-
meability and to decrease the effect of high levels of vasopressin 
in the cortical collecting duct. In vitro, Olesen et al. found that 
PGE2 increased phosphorylation and apical targeting of AQP2 in 
Madin–Darby canine kidney (MDCK) cells, that the EP4 receptor 
agonist CAY10580 had similar effects, and that the EP2 agonist 
butaprost had effects identical to those of PGE2. Moreover, both 
PGE2 and butaprost (but not CAY10580) increased cAMP in 
the cells. In cortical kidney slices, the authors found that admin-
istration of PGE2 and butaprost increased AQP2 membrane 
abundance in collecting ducts. Importantly, in vivo, the polyuria 
and severe concentrating defect induced by a V2R antagonist were 
greatly alleviated by treatment with butaprost (Figure). In con-
clusion, EP2 and EP4 agonists increase AQP2 phosphorylation 
and trafficking, probably through different signaling pathways. 
Furthermore, EP2-selective agonists can partially compensate for 
a nonfunctional V2R, providing a rationale for new treatment 
strategies for hereditary nephrogenic diabetes insipidus, which is 
due to a loss-of-function mutation of the receptor.
Juan Oliver
Effect of dietary protein 
supplementation on blood pressure: 
a randomized, controlled trial
He et al., Circulation 2011; 124: 589–595; doi:10.1161/
CIRCULATIONAHA.110.009159
Observational studies have suggested that protein restriction can 
result in a slower progression of kidney disease, although this 
observation was not confirmed in randomized trials. Conversely, 
studies suggest that protein supplementation can result in lower 
blood pressure (BP). The Protein and Blood Pressure (ProBP) 
study was a randomized double-blinded trial to test whether a 
soy protein or mild protein supplement would reduce systolic 
BP as compared with a complex carbohydrate supplement. The 
trial used a cross over design with each patient receiving each of 
the three supplements, randomized as to the order in which the 
supplements were received. Participants received 40 g soy pro-
tein, 40 g milk protein, and 40 g complex carbohydrate per day 
for a period of 8 weeks each. Subjects were 48 years old on aver-
age and had a mean systolic BP between 120 and 159 mm Hg at 
two screening visits. At initiation of the study, the mean systolic 
and diastolic BP of the patients was at 126.7/82.4 mm Hg. As 
compared with the period during which subjects were taking 
the carbohydrate supplement, the BP was 2 mm Hg lower when 
they were receiving the soy protein supplement and 2.3 mm Hg 
lower when they were receiving milk protein. Body weight, fast-
ing plasma glucose, and serum lipids did not vary significantly 
among intervention phases, except for a slightly higher high-
density lipoprotein measurement among participants receiving 
the soy protein supplement. Adverse events were related mostly 
to gastrointestinal intolerance.
This trial underscores the importance of randomized trials in 
confirming a cause-and-effect relationship between protein sup-
plementation and BP. This study demonstrated a small, but sig-
nificant, improvement at 6 months. Although not generalizable to 
those with kidney function, this study suggests a role for protein 
supplementation in the treatment of hypertension. Further stud-
ies will be required to understand the mechanism by which blood 
pressure is linked to nutrient intake.
Lynda Szczech
Effect of EP2 agonist butaprost on urine volume in rats treated with a 
V2R antagonist (OPC). Urine volume collected from 0 to 24 hours (day 1) 
and from 24 to 48 hours (day 2) from rats treated with only OPC (gray bars 
and line) or with butaprost alongside OPC (black bars and line). 
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